pharmaphorum
APRIL 23, 2021
At the moment, IgAN is controlled using blood pressure medication to limit damage to the kidney, with immunosuppressants such as corticosteroids used off-label in some cases to suppress the autoimmune response. It is usually diagnosed after patients see blood in their urine and undergo a kidney biopsy.
pharmaphorum
FEBRUARY 7, 2022
At the moment CAD is managed using off-label therapies, including rituximab and corticosteroid drugs, and sutimlimab’s potential to improve treatment earned it a breakthrough designation from the FDA. It is also being developed for other indications including immune thrombocytopenic purpura.
PharmaShots
FEBRUARY 21, 2023
threshold by 2026. Nordic is advancing the development of CD37-targeted therapies for hematological cancers and immune diseases. With the growing influence of radiopharmaceutical companies in oncology, the companies hold a firm grasp on the market.
Expert insights. Personalized for you.
52 
Let's personalize your content